- Conditions
- Neovascular (Wet) Age-Related Macular Degeneration
- Interventions
- aflibercept, High-dose aflibercept
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Encino, California + 42 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 908
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Macular Degeneration
- Interventions
- Abicipar pegol
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 32 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- E10030 plus Lucentis, Lucentis
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 449 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- West Columbia, South Carolina
- Conditions
- Age-related Macular Degeneration
- Interventions
- DCDC App
- Other
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Ranibizumab, Aflibercept
- Drug
- Lead sponsor
- Associated Retinal Consultants, Michigan
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Age-related Macular Degeneration, Age-related Maculopathy
- Interventions
- Observational-1, Observational-2
- Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 49 Years and older
- Enrollment
- 603 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Pittsburgh, Pennsylvania
- Conditions
- Macular Degeneration, Diabetic Retinopathy, Hippel-Landau Disease, Mitochondria
- Interventions
- Feasibility Study - Imaging System
- Procedure
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age-Related Macular Degeneration (AMD)
- Interventions
- PAN-90806 Ophthalmic Solution, Lucentis
- Drug
- Lead sponsor
- PanOptica, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 22
- States / cities
- Colorado Springs, Colorado • Winter Haven, Florida • Shawnee Mission, Kansas + 19 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- CTx001
- Genetic
- Lead sponsor
- Complement Therapeutics
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 4
- States / cities
- Carmel, Indiana • Reno, Nevada • Dallas, Texas + 1 more
- Conditions
- Age Related Macular Degeneration, AMD, CNV
- Interventions
- Efalizumab, Ranibizumab
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Branch Retinal Vein Occlusion
- Interventions
- Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more
- Conditions
- Macular Degeneration, Age-related, Geographic Atrophy
- Interventions
- BI 771716, Pegcetacoplan, Sham comparator to BI 771716
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 46
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
- Interventions
- OCU-10-C-110 for Injection
- Drug
- Lead sponsor
- Ocugenix Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Carmel, Indiana • Abilene, Texas • Willow Park, Texas
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Eculizumab, Saline
- Drug
- Lead sponsor
- Philip J. Rosenfeld, MD, PhD
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Uveitis
- Interventions
- Interferon Gamma 1-b
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Proton radiation
- Radiation
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- Not listed
- Lead sponsor
- Michael Abramoff
- Other
- Eligibility
- 45 Years to 120 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Age-related Macular Degeneration, Choroidal Neovascularization
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Macular Edema
- Interventions
- ranibizumab 0.5mg, ranibizumab 1.0mg
- Drug
- Lead sponsor
- Hanscom, Thomas, M.D.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- Huntington Beach, California • Long Beach, California • Santa Monica, California + 1 more
- Conditions
- Geographic Atrophy
- Interventions
- Danicopan, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Encino, California + 45 more
- Conditions
- Retinal Disease, AMD, Retinal Degeneration, Retinitis Pigmentosa
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 1 Day to 120 Years
- Enrollment
- 930 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age-related Macular Degeneration, Aging
- Interventions
- Normal Macular Health, Early Macular Degeneration, Young Normals
- Other
- Lead sponsor
- Cynthia Owsley
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 556 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Retinal Disease, Healthy
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age-Related Macular Degeneration
- Interventions
- alpha lipoic acid, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 5
- States / cities
- Iowa City, Iowa • Teaneck, New Jersey • Eugene, Oregon + 2 more